 Daily Mail |
Charity angry at NICE decision on Xolair
OnMedica Omalizumab is licensed as add-on therapy for adults and children aged at least 6 years, who have severe persistent allergic asthma and meet other criteria. … Asthma drug denied to young children UK's NICE reaffirms decision to deny use of Novartis' asthma drug Xolair for … Under-12s to be denied asthma jab only if they live in England |
View full post on asthma – Google News